2024 AF Symposium
Spotlight Session: Intranasal Etripamil in AF-RVR: Data on Efficacy for Acute Rate Control (Milestone Pharmaceuticals).

Dr. Jonathan Piccini
Dr. Jonathan Piccini from Duke University Medical Center described a novel nasal medication which could be of major benefit to patients suffering from rapid heart rate Rapid Ventricular Rate (RVR).
Rapid Ventricular Rate is Very Hard on Patients
Rapid Ventricular Rate (RVR) can be very symptomatic, disruptive, and occur far too often for many patients and usually requires visits to the emergency room (ER). But treatment in the ER often doesn’t work well and is costly both for patients and hospitals.
Etripamil Works to Slow Heart Rate and is Self-Administered
Etripamil is a calcium channel blocker (L type) sprayed into the nose for rapid absorption by the nasal mucosa (soft tissue). It works in only 7 minutes. It slows the heart rate and prolongs the refractory period of the AV Node.
It is administered by the patient themselves outside of a health care facility (such as at home).
Etripamil Safe and Effective
In blind placebo trials Etripamil has been found to be safe and effective in patients with both A-Fib and RVR. It is normally administered if the heart rate goes over 100 beats/minute. The average heart rate reduction was 29.91 beats/minute. It lasts for 150 minutes. There was a very low rate of complications. Most importantly, patient satisfaction was significant.

Editor’s Comments



